PAI-1 Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

SERPINE1 (Serpin Family E Member 1) is a protein coding gene located on human chromosome 7q22.1. SERPINE1 is also known as PAI, PAI1, PAI-1 and PLANH1. The human SERPINE1 gene encodes a 45060 Da protein containing 402 amino acids. Biased expression in gall bladder (RPKM 208.8), placenta (RPKM 164.7) and 7 other tissues Among its related pathways are Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer and E2F transcription factor network. SERPINE1 is related to signaling receptor binding and protease binding. SERPINE2 is an important paralog of SERPINE1 gene. SERPINE1 is associated with some diseases, including Plasminogen Activator Inhibitor-1 Deficiency and Hepatic Veno-Occlusive Disease.

PAI-1 Protein (3)

    PAI-1 Antibody (9)

      PAI-1 ELISA Kit & Match Antibody ELISA Pair Set (2)

      PAI-1 cDNA Clone (29)

      NM_000602.3
      NM_008871.2

      In expression vector

      NM_012620.1

      PAI-1 qPCR Primer (2)

      PAI-1 Lysate (3)

        More Product Popular With Customers

        PAI-1 Background

        Plasminogen activator inhibitor 1, also known as PAI-1, Endothelial plasminogen activator inhibitor, SerpinE1 and PLANH1, is a secreted glycoprotein that belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis. Defects in SerpinE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma. High concentrations of SerpinE1 have been associated with thrombophilia which is an autosomal dominant disorder in which affected individuals are prone to develop serious spontaneous thrombosis. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. Greater expression of PAI-1 has been associated with increased survival of cells and resistance to apoptosis. PAI-1 appears to influence apoptosis by decreasing cell adhesion (anoikis) as well as its effect on intracellular signaling. PAI-1, in its active state, also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family. The mechanisms of PAI-1 overexpression during obesity are complex, and it is conceivable that several inducers are involved at the same time at several sites of synthesis. PAI-1 is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis.

        PAI-1 References

        • Alessi MC, et al. (2006) PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 26(10): 2200-7.
        • Schneider DJ, et al. (2008) The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost. 100(6): 1037-40.
        • Dupont DM, et al. (2009) Biochemical properties of plasminogen activator inhibitor-1. Front Biosci. 14: 1337-61.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.